Istituti Clinici Scientifici Maugeri IRCCS, Unit of Internal Medicine and Endocrinology and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.
Adv Ther. 2019 Sep;36(Suppl 2):47-58. doi: 10.1007/s12325-019-01080-8. Epub 2019 Sep 4.
Hypothyroidism affects up to 5% of the general population, with a further estimated 5% being undiagnosed. Over 99% of affected patients suffer from primary hypothyroidism. Worldwide, environmental iodine deficiency is the most common cause of all thyroid disorders, including hypothyroidism, but in areas of iodine sufficiency, Hashimoto's disease (chronic autoimmune thyroiditis) is the most common cause of thyroid failure. Hypothyroidism is diagnosed biochemically, being overt primary hypothyroidism defined as serum thyroid-stimulating hormone (TSH) concentrations above and thyroxine concentrations below the normal reference range. Symptoms of hypothyroidism are non-specific and include mild to moderate weight gain, fatigue, poor concentration, depression, and menstrual irregularities, while the consequences of untreated or under-treated hypothyroidism include cardiovascular disease and increased mortality. Levothyroxine has long been the main tool for treating hypothyroidism and is one of the world's most widely prescribed medicines. In adults with overt hypothyroidism, levothyroxine is usually prescribed at a starting dose of 1.6 µg/kg/day, which is then titrated to achieve optimal TSH levels (0.4-4.0 mIU/L), according to the therapeutic target. We here summarise the history of levothyroxine and discuss future issues regarding the optimal treatment of hypothyroidism. Because nearly one-third of patients with treated hypothyroidism still exhibit symptoms, it is important that levothyroxine is used more appropriately to achieve maximum benefit for patients. In order to ensure this, further research should include more accurate assessments of the true prevalence of hypothyroidism in the community, optimisation of the levothyroxine substitution dose, proper duration of treatment, and identification of patients who may benefit from combination therapy with levothyroxine plus levotriiodothyronine.Funding: Merck.Plain Language Summary: Plain language summary available for this article.
甲状腺功能减退症影响了高达 5%的普通人群,另有 5%的患者估计未被诊断。超过 99%的受影响患者患有原发性甲状腺功能减退症。在全球范围内,环境碘缺乏是所有甲状腺疾病(包括甲状腺功能减退症)的最常见原因,但在碘充足的地区,桥本氏病(慢性自身免疫性甲状腺炎)是甲状腺功能衰竭的最常见原因。甲状腺功能减退症通过生化诊断确定,显性原发性甲状腺功能减退症定义为血清促甲状腺激素(TSH)浓度高于正常参考范围,甲状腺素浓度低于正常参考范围。甲状腺功能减退症的症状是非特异性的,包括轻度至中度体重增加、疲劳、注意力不集中、抑郁和月经不规律,而未经治疗或治疗不足的甲状腺功能减退症的后果包括心血管疾病和死亡率增加。左甲状腺素一直是治疗甲状腺功能减退症的主要工具,也是世界上最广泛使用的药物之一。在显性甲状腺功能减退症的成年人中,左甲状腺素的起始剂量通常为 1.6μg/kg/天,然后根据治疗目标滴定以达到最佳 TSH 水平(0.4-4.0mIU/L)。我们在这里总结了左甲状腺素的历史,并讨论了治疗甲状腺功能减退症的未来问题。由于近三分之一的甲状腺功能减退症患者仍有症状,因此重要的是要更恰当地使用左甲状腺素,为患者带来最大的益处。为了确保这一点,进一步的研究应该包括更准确地评估社区中真正的甲状腺功能减退症患病率,优化左甲状腺素替代剂量,适当的治疗持续时间,以及确定哪些患者可能受益于左甲状腺素联合左三碘甲状腺原氨酸的联合治疗。
默克公司。
本文提供了普通语言摘要。